Disclaimer: Cellular Engineering Technologies and the John Paul II Medical Research Institute does not make any claim that induced pluripotent stem cells will cure or treat any specific disease. We are only providing the best medical and scientific information and state-of-the-art at this time in the field of regenerative medicine for the consumer based on the known shortcomings of cord blood banking, drug development and diagnostics.
In response to requests from the public to CET and JP2MRI's publication on its next generation iPSC technology, we are currently accepting names for a waiting list from the public to produce a personalized iPSC from privately banked cord blood or from peripheral blood from individuals below the age of 40. CET is currently offering an introductory promotional discount of 20 percent discount on our iPSC service for those consumers who sign up on this waiting list.